Moderate to Severe

Juvenile Idiopathic Arthritis

Non-Infectious

Intermediate, Posterior and Panuveitis

Active

Psoriatic Arthritis

Moderate to Severe

Hidradenitis Suppurativa

Refractory, Moderate to Severe

Atopic Dermatitis

Gastroenterology

Moderate to Severe

Crohn's Disease

Moderate to Severe

Pediatric Crohn's Disease

Moderate to Severe

Ulcerative Colitis

Moderate to Severe

Pediatric Ulcerative Colitis

Ophthalmology

Non-Infectious

Intermediate, Posterior and Panuveitis

DOWNLOADABLE

R E S O U R C E S

Help your patients start and stay on track with their prescribed treatment.
Explore resources and download the forms you need to get started.

Filter by Indication

All Resources Practice

INSURANCE AUTHORIZATIONS

Prior Authorizations (PAs)

Get help navigating the general PA process.

Appeal Letter Template

If a patient is denied coverage, the following template and instructions can be used to help draft an appeal letter.

Letter of Medical Necessity (LMN) Template

If medical necessity must be shown to gain coverage or formulary exception, the following instructions and template may help.

EXCEPTION LETTERS

Formulary Exception Letter Templates

A formulary exception letter may be able to help a patient gain access by outlining the reasons why a treatment is necessary to meet the medical needs of a patient.

Formulary Exception Letter (Rheumatology)

Formulary Exception Letter (Dermatology)

Tiering Exception Letter

DOSING AND CODING GUIDES

RINVOQ Dosing Guide
(Rheumatology)

RINVOQ Dosing Guide
(Atopic Dermatitis)

Coding Guide

SPECIALTY PHARMACY

Specialty Pharmacy Contacts Guide

EDUCATIONAL RESOURCES

PsA Minimal Disease Activity (MDA) Flashcard

All Resources Patient

COMPLETE

RINVOQ Complete Enrollment & Prescription Form (Rheumatology)

RINVOQ Complete Enrollment & Prescription Form (Dermatology - Adults)

RINVOQ Complete Enrollment & Prescription Form (Dermatology -
Pediatrics 12+ Years)

INSURANCE AND BENEFITS

Benefits Verification Chart

Insurance Comparison Booklet

HIPAA AUTHORIZATION

HIPAA Authorization Form

WELCOME RESOURCES

RINVOQ RA Patient Brochure

RINVOQ PsA Patient Brochure

RINVOQ AD Patient Brochure

Moderate to Severe

RHEUMATOID ARTHRITIS

Practice Resources

RINVOQ Dosing Guide (Rheumatology)

Formulary Exception Letter (Rheumatology)

Patient Resources

RINVOQ RA Patient Brochure

RINVOQ Complete Brochure (Rheumatology)

Active

PSORIATIC ARTHRITIS

Practice Resources

RINVOQ Dosing Guide (Rheumatology)

Formulary Exception Letter (Rheumatology)

PsA Minimal Disease Activity (MDA) Flashcard

Patient Resources

RINVOQ PsA Patient Brochure

RINVOQ Complete Brochure (Rheumatology)

Refractory, Moderate to Severe

ATOPIC DERMATITIS

Practice Resources

RINVOQ Dosing Guide
(Atopic Dermatitis)

Formulary Exception Letter
(Dermatology)

Patient Resources

RINVOQ AD Patient Brochure

RINVOQ Complete Brochure (Atopic Dermatitis - Adult)

RINVOQ Complete Brochure (Atopic Dermatitis -
Pediatrics 12+ Years)

AD=atopic dermatitis; PsA=psoriatic arthritis; RA=rheumatoid arthritis.

IMPORTANT SAFETY INFORMATION & INDICATIONS1

INDICATIONS1

RINVOQ is indicated for the treatment of:

  • Moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to one or more TNF blockers.
  • Active psoriatic arthritis in adults who have had an inadequate response or intolerance to one or more TNF blockers.

Limitations of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants, such as azathioprine and cyclosporine, is not recommended.

  • Refractory, moderate to severe atopic dermatitis in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.

Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.

SERIOUS INFECTIONS

  • Active tuberculosis (TB), which may present with pulmonary or extrapulmonary disease. Test patients for latent TB before RINVOQ use and during therapy. Consider treatment for latent TB infection prior to RINVOQ use.
  • Invasive fungal infections, including cryptococcosis and pneumocystosis.
  • Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens.

MORTALITY

MALIGNANCIES

MAJOR ADVERSE CARDIOVASCULAR EVENTS

THROMBOSIS

HYPERSENSITIVITY

GASTROINTESTINAL PERFORATIONS

LABORATORY ABNORMALITIES

EMBRYO-FETAL TOXICITY

VACCINATION

LACTATION

HEPATIC IMPAIRMENT

ADVERSE REACTIONS

REFERENCE:

  1. RINVOQ [package insert]. North Chicago, IL: AbbVie Inc.

INDICATIONS & LIMITATIONS OF USE1

RINVOQ is indicated for the treatment of:

  • Moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to one or more TNF blockers.
  • Active psoriatic arthritis in adults who have had an inadequate response or intolerance to one or more TNF blockers.

Limitations of Use: Use of RINVOQ in combination with other JAK …

IMPORTANT SAFETY INFORMATION1

WARNING: Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis.

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant …

IMPORTANT SAFETY INFORMATION1

WARNING: Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis.

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant …

INDICATIONS & LIMITATIONS OF USE1

RINVOQ is indicated for the treatment of:

  • Moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to one or more TNF blockers.
  • Active psoriatic arthritis in adults who have had an inadequate response or intolerance to one or more TNF blockers.

Limitations of Use: Use of RINVOQ in combination with other JAK …

IMPORTANT SAFETY INFORMATION1

WARNING: Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis.

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant …

IMPORTANT SAFETY INFORMATION1

WARNING: Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis.

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant …

IMPORTANT SAFETY INFORMATION & INDICATIONS1

INDICATIONS1

RINVOQ is indicated for the treatment of:

  • Moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to one or more TNF blockers.
  • Active psoriatic arthritis in adults who have had an inadequate response or intolerance to one or more TNF blockers.

Limitations of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants, such as azathioprine and cyclosporine, is not recommended.

  • Refractory, moderate to severe atopic dermatitis in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.

Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.

SERIOUS INFECTIONS

  • Active tuberculosis (TB), which may present with pulmonary or extrapulmonary disease. Test patients for latent TB before RINVOQ use and during therapy. Consider treatment for latent TB infection prior to RINVOQ use.
  • Invasive fungal infections, including cryptococcosis and pneumocystosis.
  • Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens.

MORTALITY

MALIGNANCIES

MAJOR ADVERSE CARDIOVASCULAR EVENTS

THROMBOSIS

HYPERSENSITIVITY

GASTROINTESTINAL PERFORATIONS

LABORATORY ABNORMALITIES

EMBRYO-FETAL TOXICITY

VACCINATION

LACTATION

HEPATIC IMPAIRMENT

ADVERSE REACTIONS